KOREA WHO
-
-
CEO of STCube
Jung Hyun-jin
Former SNUH Doctor-Turned Owner Leads Nelmastobart Commercialization
-
Last Updated on Feb 3, 2026
-
CEO of STCube
Copy Url : https://www.koreawho.com/profile/JungHyunjin- Life Summary
Jung Hyun-jin is the CEO of STCube.
He is focusing on the clinical development of the company’s core pipeline, ‘Nelmastobart (hSTC810)’. He is also accelerating efforts to license Nelmastobart to global big pharma companies.
He was born on September 23, 1964, in Hamyang, South Gyeongsang Province.
He graduated from Seoul National University College of Medicine, earned a master’s degree in medicine at Seoul National University Graduate School, and completed a doctoral course.
He worked as a clinical fellow in the Department of Clinical Pathology at Seoul National University Hospital before founding InnoCell in 2002.
After selling InnoCell to Green Cross (now GC Green Cross), he acquired STCube in 2013.
He also serves as CEO of Biomedical Holdings.
He is a physician-turned-owner who developed the liver cancer treatment Immuncell-LC. He is regarded as one of the pioneers who opened the field of immune-oncology drugs in South Korea.
#JungHyunjin #STCube #biotechnology #immunooncology #NelmaStobart #hSTC810 #livercancer #ImmuncellLC #Koreanbiotech #drugdevelopment
He is focusing on the clinical development of the company’s core pipeline, ‘Nelmastobart (hSTC810)’. He is also accelerating efforts to license Nelmastobart to global big pharma companies.
He was born on September 23, 1964, in Hamyang, South Gyeongsang Province.
He graduated from Seoul National University College of Medicine, earned a master’s degree in medicine at Seoul National University Graduate School, and completed a doctoral course.
He worked as a clinical fellow in the Department of Clinical Pathology at Seoul National University Hospital before founding InnoCell in 2002.
After selling InnoCell to Green Cross (now GC Green Cross), he acquired STCube in 2013.
He also serves as CEO of Biomedical Holdings.
He is a physician-turned-owner who developed the liver cancer treatment Immuncell-LC. He is regarded as one of the pioneers who opened the field of immune-oncology drugs in South Korea.
#JungHyunjin #STCube #biotechnology #immunooncology #NelmaStobart #hSTC810 #livercancer #ImmuncellLC #Koreanbiotech #drugdevelopment
- Life Summary
- Career Highlights & Challenges
- · STCube’s Business Overview
- · STCube’s Governance Structure
- · Nelmastobart Begins Phase 2 Dosing for NSCLC
- · Metastatic Colorectal Cancer Phase 1b/2 Enrollment Completed
- · Industrial Lens Module Sales Plunge, Cosmetics Revenue Grows
- · STCube Acquired via Third-Party Capital Increase
- · Founded InnoCell, Developed Cancer Immunotherapy, Later Sold to Green Cross
- · STCube’s Journey
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Additional Information
- Notable Quotations
- Infographic & Photos